Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrr...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Zhiying Cindy Xu, Carmelo Carlo-Stella
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Ferrata Storti Foundation 2023-08-01
Cyfres:Haematologica
Mynediad Ar-lein:https://haematologica.org/article/view/11243

Rhyngrwyd

https://haematologica.org/article/view/11243

Eitemau Tebyg